Revolution Medicines, Inc. (RVMD) Tops Q4 EPS by 19c

Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q4 EPS of ($0.63), $0.19 better than the analyst estimate of ($0.82). Revenue for the quarter came in at $15.33 million versus the consensus estimate of $7.8 million.

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• UBS Upgrades Feng Tay Enterprises (9910:TT) to Buy